Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

dHACM - MiMedx

Drug Profile

dHACM - MiMedx

Alternative Names: AmnioFix®; Amniotic cell therapy - MiMedix; Dehydrated human amnion/chorion allograft; Dehydrated human amnion/chorion membrane; Dehydrated human amniotic membrane; Dehydrated human amniotic membrane micronised; Human amniotic membrane allograft - MiMedix; mdHACM; Micronised dehydrated human amniotic membrane; Micronised tissue allografts - MiMedx; Micronised-dHACM; Micronized dHACM

Latest Information Update: 30 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MiMedx
  • Class Cell therapies; Tissue extracts
  • Mechanism of Action Cell replacements; Cell stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Plantar fasciitis; Tendinitis
  • Phase II Wounds
  • Suspended Osteoarthritis
  • No development reported Ischaemia; Shoulder injuries

Most Recent Events

  • 15 Dec 2023 MiMedx terminates a phase IIb trial for Osteoarthritis in the USA (Parenteral, Injection) due to sponsor's decision(NCT05796765)
  • 20 Jun 2023 Suspended - Phase-II for Osteoarthritis (In the elderly, In adults) in USA (Parenteral)
  • 20 Jun 2023 Suspended - Phase-III for Osteoarthritis (Intra-arterial)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top